ReviewCurrent opinion in allergy and clinical immunology2017
Allergen immunotherapy: an updated review of safety.
Review in Current opinion in allergy and clinical immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06523478 (A Study on the Efficacy and Safety of Intratonsillar Immunotherapy for Allergic Rhinitis), which is not on this map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study on the Efficacy and Safety of Intratonsillar Immunotherapy for Allergic Rhinitis
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 151 citations in OpenAlex.
- Efficacy and safety of intralymphatic immunotherapy for allergic rhinitis: an overview of systematic reviews and meta analyses.Frontiers in medicine · 2025Pooled it
- A multicenter randomized study: safety of an optimized accelerated house dust mite immunotherapy for patients with allergic rhinitis in China (PERFECT study).Frontiers in immunology · 2026Trial
- Clinical Trial With a Depigmented, Polymerized Mite Mixture Extract at Maximum Concentrations.Immunity, inflammation and disease · 2024Trial
- Indications for Biological Treatment Combined with Allergen-Specific Immunotherapy: Who Is It Really Intended for?Journal of clinical medicine · 2026Review
- Dupilumab Combined With House Dust Mite Allergen Immunotherapy for Atopic Dermatitis: A Systematic Review and Meta-Analysis.Clinical and translational allergy · 2026Review
- Bioengineering Interventions to Enhance the Capacity of the Gut Microbiota in Controlling Food Allergies.Life (Basel, Switzerland) · 2026Review
- Safety and Effectiveness of Subcutaneous Immunotherapy with a Glutaraldehyde-Polymerized Mite Allergen Extract in Adults and Children with Allergic Rhinitis with or Without Asthma Due toDiseases (Basel, Switzerland) · 2026Article
- Adjuvant Strategies to Improve the Efficacy of Allergen Immunotherapy.Journal of inflammation research · 2026Review
- Evaluation of the Quality and Reliability of ChatGPT-4's Responses on Allergen Immunotherapy Using Validated Instruments for Health Information Quality Assessment.Clinical and translational allergy · 2025Article
- Methyltransferase-like 3-mediated RNA NFrontiers in immunology · 2025Review
- Safety and Effectiveness of Allergen Immunotherapy in Patients with Severe Allergic Asthma.Journal of asthma and allergy · 2025Article
- A dominant, pan-DR binding epitope of Der p 1 in house dust mite allergy induces tolerance in HLA-DR4 transgenic mice.Frontiers in immunology · 2025Article
- RIAIT (Italian Registry of Allergen Immunotherapy): Protocol for a New Tool in a New Vision of Disease-Modifying Therapy for Allergists.Journal of personalized medicine · 2024Article
- Improving allergy management and treatment: a proposed algorithm and curriculum for prescribing allergen immunotherapy in the primary care setting.NPJ primary care respiratory medicine · 2024Article
- Single-Domain Antibodies-Novel Tools to Study and Treat Allergies.International journal of molecular sciences · 2024Review
- Safety of 300IR house dust mite sublingual tablet from pooled clinical trial and post-marketing data.The World Allergy Organization journal · 2024Article
- Allergen immunotherapy in patients with severe asthma: A need for prospective trials.Pediatric pulmonology · 2024Article
- Article
- Advancements in Allergen Immunotherapy for the Treatment of Atopic Dermatitis.International journal of molecular sciences · 2024Review
- Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens.Immunotherapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewAllergen immunotherapy is the only modality that can modify the immune response upon exposure to aeroallergens and venom allergens. This review will update the allergist on recent studies evaluating safety of sublingual and subcutaneous allergen immunotherapy. RECENT
findingsMultiple clinical trials and retrospective studies have been published evaluating overall safety of these therapies. The risk of systemic reactions with subcutaneous immunotherapy remains quite low, but near-fatal and fatal anaphylaxis does occur, requiring physicians to be aware of potential risks for such events. Sublingual immunotherapy has a high incidence of local site application reactions, but severe anaphylactic events are very uncommon. SUMMARY: Subcutaneous immunotherapy and sublingual immunotherapy are beneficial in treating allergic rhinitis and venom hypersensitivity but should be administered only by physicians familiar with potential risk factors and able to manage treatment-related local and systemic allergic reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.